Skip to main content
Erschienen in: Tumor Biology 4/2014

01.04.2014 | Research Article

Association between a functional insertion/deletion polymorphism in IL1A gene and risk of papillary thyroid carcinoma

verfasst von: Linbo Gao, Xinxin Zhu, Zhihui Li, Lijuan Li, Tao Wang, Huaizhong Hu, Wanli Guo, Peng Chen, Jingqiang Zhu, Lin Zhang

Erschienen in: Tumor Biology | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study was to evaluate whether an insertion/deletion polymorphism (rs3783553) locating in the miR-122 target gene IL1A 3′ untranslated region was related to the risk of papillary thyroid carcinoma (PTC). Genomic DNA was extracted from peripheral venous blood of 273 patients with PTC and 509 controls. The IL1A rs3783553 polymorphism was genotyped by using a polymerase chain reaction assay. No significant difference of the distribution of the IL1A rs3783553 polymorphism was observed between PTC patients and controls. However, patients carrying the IL1A rs3783553 ins/ins genotype and ins allele had significantly decreased risks for developing T3 and T4 when compared with patients carrying the IL1A rs3783553 del/del genotype and del allele (ins/ins vs. del/del: OR = 0.22, 95 % confidence interval (CI), 0.09–0.54; ins vs. del: OR = 0.58, 95 % CI, 0.41–0.83, respectively). These results suggest that the rs3783553 polymorphism may be used as a genetic marker to predict the size/extension of PTC.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.PubMedCrossRef Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277–300.PubMedCrossRef
2.
Zurück zum Zitat Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115(16):3801–7.PubMedCrossRef Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. Cancer. 2009;115(16):3801–7.PubMedCrossRef
3.
Zurück zum Zitat Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164–7.PubMedCrossRef Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA. 2006;295(18):2164–7.PubMedCrossRef
4.
Zurück zum Zitat Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treat Rev. 2005;31(6):423–38.PubMedCrossRef Sakorafas GH, Giotakis J, Stafyla V. Papillary thyroid microcarcinoma: a surgical perspective. Cancer Treat Rev. 2005;31(6):423–38.PubMedCrossRef
5.
Zurück zum Zitat Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.PubMedCrossRef Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.PubMedCrossRef
6.
Zurück zum Zitat Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3′ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis. 2009;30(12):2064–9.PubMedCrossRef Gao Y, He Y, Ding J, Wu K, Hu B, Liu Y, et al. An insertion/deletion polymorphism at miRNA-122-binding site in the interleukin-1alpha 3′ untranslated region confers risk for hepatocellular carcinoma. Carcinogenesis. 2009;30(12):2064–9.PubMedCrossRef
7.
Zurück zum Zitat Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008;105(20):7269–74.PubMedCentralPubMedCrossRef Jazdzewski K, Murray EL, Franssila K, Jarzab B, Schoenberg DR, de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A. 2008;105(20):7269–74.PubMedCentralPubMedCrossRef
8.
Zurück zum Zitat Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008;68(20):8535–40.PubMedCentralPubMedCrossRef Chin LJ, Ratner E, Leng S, Zhai R, Nallur S, Babar I, et al. A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res. 2008;68(20):8535–40.PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Landi D, Moreno V, Guino E, Vodicka P, Pardini B, Naccarati A, et al. Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer. Mutat Res. 2011;717(1–2):109–15.PubMedCrossRef Landi D, Moreno V, Guino E, Vodicka P, Pardini B, Naccarati A, et al. Polymorphisms affecting micro-RNA regulation and associated with the risk of dietary-related cancers: a review from the literature and new evidence for a functional role of rs17281995 (CD86) and rs1051690 (INSR), previously associated with colorectal cancer. Mutat Res. 2011;717(1–2):109–15.PubMedCrossRef
10.
Zurück zum Zitat Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis. 2008;29(3):579–84.PubMedCrossRef Landi D, Gemignani F, Naccarati A, Pardini B, Vodicka P, Vodickova L, et al. Polymorphisms within micro-RNA-binding sites and risk of sporadic colorectal cancer. Carcinogenesis. 2008;29(3):579–84.PubMedCrossRef
11.
Zurück zum Zitat Li ZH, Pan X, Han BW, Guo XM, Zhang Z, Jia J, et al. A let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancer. Tumour Biol. 2013;34(5):3159–63. Li ZH, Pan X, Han BW, Guo XM, Zhang Z, Jia J, et al. A let-7 binding site polymorphism rs712 in the KRAS 3′ UTR is associated with an increased risk of gastric cancer. Tumour Biol. 2013;34(5):3159–63.
12.
Zurück zum Zitat Yang ZH, Dai Q, Zhong L, Zhang X, Guo QX, Li SN. Association of IL-1 polymorphisms and IL-1 serum levels with susceptibility to nasopharyngeal carcinoma. Mol Carcinog. 2011;50(3):208–14.PubMedCrossRef Yang ZH, Dai Q, Zhong L, Zhang X, Guo QX, Li SN. Association of IL-1 polymorphisms and IL-1 serum levels with susceptibility to nasopharyngeal carcinoma. Mol Carcinog. 2011;50(3):208–14.PubMedCrossRef
13.
Zurück zum Zitat Zeng XF, Li J, Li SB. A functional polymorphism in IL-1A gene is associated with a reduced risk of gastric cancer. Tumour Biol. 2013;35(1):265–268 Zeng XF, Li J, Li SB. A functional polymorphism in IL-1A gene is associated with a reduced risk of gastric cancer. Tumour Biol. 2013;35(1):265–268
14.
Zurück zum Zitat Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.PubMedCrossRef Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.PubMedCrossRef
15.
Zurück zum Zitat Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A. 2009;106(5):1502–5.PubMedCentralPubMedCrossRef Jazdzewski K, Liyanarachchi S, Swierniak M, Pachucki J, Ringel MD, Jarzab B, et al. Polymorphic mature microRNAs from passenger strand of pre-miR-146a contribute to thyroid cancer. Proc Natl Acad Sci U S A. 2009;106(5):1502–5.PubMedCentralPubMedCrossRef
16.
Zurück zum Zitat Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol. 2008;82(16):8215–23.PubMedCentralPubMedCrossRef Chang J, Guo JT, Jiang D, Guo H, Taylor JM, Block TM. Liver-specific microRNA miR-122 enhances the replication of hepatitis C virus in nonhepatic cells. J Virol. 2008;82(16):8215–23.PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat Reddi HV, Madde P, Milosevic D, Hackbarth JS, Algeciras-Schimnich A, McIver B, et al. The putative PAX8/PPARgamma fusion oncoprotein exhibits partial tumor suppressor activity through up-regulation of micro-RNA-122 and dominant-negative PPARgamma activity. Genes Cancer. 2011;2(1):46–55.PubMedCentralPubMedCrossRef Reddi HV, Madde P, Milosevic D, Hackbarth JS, Algeciras-Schimnich A, McIver B, et al. The putative PAX8/PPARgamma fusion oncoprotein exhibits partial tumor suppressor activity through up-regulation of micro-RNA-122 and dominant-negative PPARgamma activity. Genes Cancer. 2011;2(1):46–55.PubMedCentralPubMedCrossRef
18.
Zurück zum Zitat Reddi HV, Driscoll CB, Madde P, Milosevic D, Hurley RM, McDonough SJ, et al. Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARgamma fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. Cancer Gene Ther. 2013;20(5):267–75.PubMedCrossRef Reddi HV, Driscoll CB, Madde P, Milosevic D, Hurley RM, McDonough SJ, et al. Redifferentiation and induction of tumor suppressors miR-122 and miR-375 by the PAX8/PPARgamma fusion protein inhibits anaplastic thyroid cancer: a novel therapeutic strategy. Cancer Gene Ther. 2013;20(5):267–75.PubMedCrossRef
20.
Zurück zum Zitat Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605–21.PubMedCrossRef Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol. 2006;72(11):1605–21.PubMedCrossRef
21.
Zurück zum Zitat Apte RN, Voronov E. Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol Rev. 2008;222(1):222–41.PubMedCrossRef Apte RN, Voronov E. Is interleukin-1 a good or bad ‘guy’ in tumor immunobiology and immunotherapy? Immunol Rev. 2008;222(1):222–41.PubMedCrossRef
22.
Zurück zum Zitat Kimura H, Yamashita S, Namba H, Tominaga T, Tsuruta M, Yokoyama N, et al. Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab. 1992;75(2):596–602.PubMed Kimura H, Yamashita S, Namba H, Tominaga T, Tsuruta M, Yokoyama N, et al. Interleukin-1 inhibits human thyroid carcinoma cell growth. J Clin Endocrinol Metab. 1992;75(2):596–602.PubMed
23.
Zurück zum Zitat Kammoun-Krichen M, Bougacha-Elleuch N, Mnif M, Bougacha F, Charffedine I, Rebuffat S, et al. IL-1beta a potential factor for discriminating between thyroid carcinoma and atrophic thyroiditis. Eur Cytokine Netw. 2012;23(3):101–6.PubMed Kammoun-Krichen M, Bougacha-Elleuch N, Mnif M, Bougacha F, Charffedine I, Rebuffat S, et al. IL-1beta a potential factor for discriminating between thyroid carcinoma and atrophic thyroiditis. Eur Cytokine Netw. 2012;23(3):101–6.PubMed
24.
Zurück zum Zitat Zeki K, Nakano Y, Inokuchi N, Watanabe K, Morimoto I, Yamashita U, et al. Autocrine stimulation of interleukin-1 in the growth of human thyroid carcinoma cell line NIM 1. J Clin Endocrinol Metab. 1993;76(1):127–33.PubMed Zeki K, Nakano Y, Inokuchi N, Watanabe K, Morimoto I, Yamashita U, et al. Autocrine stimulation of interleukin-1 in the growth of human thyroid carcinoma cell line NIM 1. J Clin Endocrinol Metab. 1993;76(1):127–33.PubMed
25.
Zurück zum Zitat Zeki K, Morimoto I, Arao T, Eto S, Yamashita U. Interleukin-1alpha regulates G1 cell cycle progression and arrest in thyroid carcinoma cell lines NIM1 and NPA. J Endocrinol. 1999;160(1):67–73.PubMedCrossRef Zeki K, Morimoto I, Arao T, Eto S, Yamashita U. Interleukin-1alpha regulates G1 cell cycle progression and arrest in thyroid carcinoma cell lines NIM1 and NPA. J Endocrinol. 1999;160(1):67–73.PubMedCrossRef
26.
Zurück zum Zitat Inokuchi N, Zeki K, Morimoto I, Nakano Y, Fujihira T, Yamashita U, et al. Stimulatory effect of interleukin-1 alpha on proliferation through a Ca2+/calmodulin-dependent pathway of a human thyroid carcinoma cell line, NIM 1. Jpn J Cancer Res. 1995;86(7):670–6.PubMedCrossRef Inokuchi N, Zeki K, Morimoto I, Nakano Y, Fujihira T, Yamashita U, et al. Stimulatory effect of interleukin-1 alpha on proliferation through a Ca2+/calmodulin-dependent pathway of a human thyroid carcinoma cell line, NIM 1. Jpn J Cancer Res. 1995;86(7):670–6.PubMedCrossRef
27.
Zurück zum Zitat Zhang HT. Int7G24A variant of the TGFBR1 gene and cancer risk: a meta-analysis of three case-control studies. Lung Cancer. 2005;49(3):419–20.PubMedCrossRef Zhang HT. Int7G24A variant of the TGFBR1 gene and cancer risk: a meta-analysis of three case-control studies. Lung Cancer. 2005;49(3):419–20.PubMedCrossRef
28.
Zurück zum Zitat Lu D, Chen L, Shi X, Zhang X, Ling X, Chen X, et al. A functional polymorphism in interleukin-1alpha (IL1A) gene is associated with risk of alopecia areata in Chinese populations. Gene. 2013;521(2):282–6.PubMedCrossRef Lu D, Chen L, Shi X, Zhang X, Ling X, Chen X, et al. A functional polymorphism in interleukin-1alpha (IL1A) gene is associated with risk of alopecia areata in Chinese populations. Gene. 2013;521(2):282–6.PubMedCrossRef
Metadaten
Titel
Association between a functional insertion/deletion polymorphism in IL1A gene and risk of papillary thyroid carcinoma
verfasst von
Linbo Gao
Xinxin Zhu
Zhihui Li
Lijuan Li
Tao Wang
Huaizhong Hu
Wanli Guo
Peng Chen
Jingqiang Zhu
Lin Zhang
Publikationsdatum
01.04.2014
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 4/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1512-6

Weitere Artikel der Ausgabe 4/2014

Tumor Biology 4/2014 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.